Connect Biopharma is trading 5.64% up now at $1.24, as investors reassess September 15 Phase 2 asthma data after the stock fell 32.17% to $1.17.
- Rademikibart improved lung function but missed statistical significance on the primary treatment-failure endpoint.
- No new company-specific announcement or reliable report clearly explains the September 16 rebound.
- Broader biotech sentiment remains weak, with XBI down 2.11%, an opposing sector influence.